FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281566897> ?p ?o ?g. }

• W4281566897 endingPage "e004345" @default.
• W4281566897 startingPage "e004345" @default.
• W4281566897 abstract "Background Therapeutic cancer vaccines represent a promising approach to improve clinical outcomes with immune checkpoint inhibition. UV1 is a second generation telomerase-targeting therapeutic cancer vaccine being investigated across multiple indications. Although telomerase is a near-universal tumor target, different treatment combinations applied across indications may affect the induced immune response. Three phase I/IIa clinical trials covering malignant melanoma, non-small cell lung cancer, and prostate cancer have been completed, with patients in follow-up for up to 8 years. Methods 52 patients were enrolled across the three trials. UV1 was given as monotherapy in the lung cancer trial and concurrent with combined androgen blockade in the prostate cancer trial. In the melanoma study, patients initiated ipilimumab treatment 1 week after the first vaccine dose. Patients were followed for UV1-specific immune responses at frequent intervals during vaccination, and every 6 months for up to 8 years in a follow-up period. Phenotypic and functional characterizations were performed on patient-derived vaccine-specific T cell responses. Results In total, 78.4% of treated patients mounted a measurable vaccine-induced T cell response in blood. The immune responses in the malignant melanoma trial, where UV1 was combined with ipilimumab, occurred more rapidly and frequently than in the lung and prostate cancer trials. In several patients, immune responses peaked years after their last vaccination. An in-depth characterization of the immune responses revealed polyfunctional CD4+ T cells producing interferon-γ and tumor necrosis factor-α on interaction with their antigen. Conclusion Long-term immunomonitoring of patients showed highly dynamic and persistent telomerase peptide-specific immune responses lasting up to 7.5 years after the initial vaccination, suggesting a plausible functional role of these T cells in long-term survivors. The superior immune response kinetics observed in the melanoma study substantiate the rationale for future combinatorial treatment strategies with UV1 vaccination and checkpoint inhibition for rapid and frequent induction of anti-telomerase immune responses in patients with cancer." @default.
• W4281566897 created "2022-05-27" @default.
• W4281566897 creator A5003293427 @default.
• W4281566897 creator A5016643816 @default.
• W4281566897 creator A5020151936 @default.
• W4281566897 creator A5024559548 @default.
• W4281566897 creator A5029207281 @default.
• W4281566897 creator A5035129840 @default.
• W4281566897 creator A5044514299 @default.
• W4281566897 creator A5071545176 @default.
• W4281566897 creator A5071850607 @default.
• W4281566897 creator A5076142358 @default.
• W4281566897 creator A5083493986 @default.
• W4281566897 date "2022-05-01" @default.
• W4281566897 modified "2023-10-18" @default.
• W4281566897 title "Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials" @default.
• W4281566897 cites W1519576779 @default.
• W4281566897 cites W1983954483 @default.
• W4281566897 cites W1985641439 @default.
• W4281566897 cites W1991098068 @default.
• W4281566897 cites W2000971601 @default.
• W4281566897 cites W2013305758 @default.
• W4281566897 cites W2024794399 @default.
• W4281566897 cites W2030976397 @default.
• W4281566897 cites W2037236933 @default.
• W4281566897 cites W2042897772 @default.
• W4281566897 cites W2046161326 @default.
• W4281566897 cites W2071544653 @default.
• W4281566897 cites W2079696222 @default.
• W4281566897 cites W2096176330 @default.
• W4281566897 cites W2097995306 @default.
• W4281566897 cites W2100789415 @default.
• W4281566897 cites W2115176808 @default.
• W4281566897 cites W2115180633 @default.
• W4281566897 cites W2138090230 @default.
• W4281566897 cites W2149467956 @default.
• W4281566897 cites W2149764521 @default.
• W4281566897 cites W2154837214 @default.
• W4281566897 cites W2170798594 @default.
• W4281566897 cites W2294927533 @default.
• W4281566897 cites W2317623391 @default.
• W4281566897 cites W2331040770 @default.
• W4281566897 cites W2520413959 @default.
• W4281566897 cites W2587242369 @default.
• W4281566897 cites W2605219687 @default.
• W4281566897 cites W2613362156 @default.
• W4281566897 cites W2724264513 @default.
• W4281566897 cites W2728365508 @default.
• W4281566897 cites W2782007611 @default.
• W4281566897 cites W2799739596 @default.
• W4281566897 cites W2884754721 @default.
• W4281566897 cites W2887577080 @default.
• W4281566897 cites W2904803926 @default.
• W4281566897 cites W2964770583 @default.
• W4281566897 cites W2991240940 @default.
• W4281566897 cites W3012105756 @default.
• W4281566897 cites W3012475590 @default.
• W4281566897 cites W3032578076 @default.
• W4281566897 cites W3037013420 @default.
• W4281566897 cites W3046115489 @default.
• W4281566897 cites W3093383535 @default.
• W4281566897 cites W3100353871 @default.
• W4281566897 cites W3108917661 @default.
• W4281566897 cites W3130718611 @default.
• W4281566897 cites W3147495190 @default.
• W4281566897 cites W3161047938 @default.
• W4281566897 cites W3180311504 @default.
• W4281566897 cites W3190141506 @default.
• W4281566897 cites W4200495164 @default.
• W4281566897 doi "https://doi.org/10.1136/jitc-2021-004345" @default.
• W4281566897 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35613827" @default.
• W4281566897 hasPublicationYear "2022" @default.
• W4281566897 type Work @default.
• W4281566897 citedByCount "10" @default.
• W4281566897 countsByYear W42815668972022 @default.
• W4281566897 countsByYear W42815668972023 @default.
• W4281566897 crossrefType "journal-article" @default.
• W4281566897 hasAuthorship W4281566897A5003293427 @default.
• W4281566897 hasAuthorship W4281566897A5016643816 @default.
• W4281566897 hasAuthorship W4281566897A5020151936 @default.
• W4281566897 hasAuthorship W4281566897A5024559548 @default.
• W4281566897 hasAuthorship W4281566897A5029207281 @default.
• W4281566897 hasAuthorship W4281566897A5035129840 @default.
• W4281566897 hasAuthorship W4281566897A5044514299 @default.
• W4281566897 hasAuthorship W4281566897A5071545176 @default.
• W4281566897 hasAuthorship W4281566897A5071850607 @default.
• W4281566897 hasAuthorship W4281566897A5076142358 @default.
• W4281566897 hasAuthorship W4281566897A5083493986 @default.
• W4281566897 hasBestOaLocation W42815668971 @default.
• W4281566897 hasConcept C104317684 @default.
• W4281566897 hasConcept C121608353 @default.
• W4281566897 hasConcept C126322002 @default.
• W4281566897 hasConcept C143998085 @default.
• W4281566897 hasConcept C147483822 @default.
• W4281566897 hasConcept C203014093 @default.
• W4281566897 hasConcept C22070199 @default.
• W4281566897 hasConcept C2776256026 @default.
• W4281566897 hasConcept C2777658100 @default.

• next